Fueled by curiosity, guided by compassion, and driven by science, I strive to transform laboratory discoveries into real-world impact through research, education, and innovation.
Fueled by curiosity, guided by compassion, and driven by science, I strive to transform laboratory discoveries into real-world impact through research, education, and innovation.
Dr. Mir S. Adil, PharmD, PhD, is an Assistant Professor of Pharmacology at DeBusk College of Osteopathic Medicine, Lincoln Memorial University. He has a passion for understanding pulmonary and immune regulation and for developing innovative strategies to treat complex diseases. A former postdoctoral scientist at Stanford University, his research explores the intersection of innate immunity, retroviral elements, and signaling pathways in autoimmune conditions such as pulmonary hypertension and cancer.
Dr. Adil is also a committed mentor and educator with experience across international institutions. As a faculty member at a medical school, he integrates research, teaching, and service to inspire the next generation of healthcare leaders. In addition to his academic roles, Dr. Adil serves as Editor for multiple reputed scientific journals, contributing to the advancement and integrity of biomedical research publishing.
Lincoln Memorial University, USA
Assistant Professor
Stanford University, USA
Postdoctoral Scientist
PhD - Clinical & Experimental Therapeutics
University of Georgia, USA
PharmD
Jawaharlal Nehru Technological University, India
Dr. Adil's interest in research began during his PharmD training, when he encountered several cases of severe drug-induced adverse reactions during clinical rotations. These experiences inspired a long-term commitment to improving patient safety and optimizing therapeutic outcomes. His first research project investigated adverse drug reactions among patients admitted to the intensive care unit, laying the foundation for a career focused on understanding the mechanisms underlying drug-induced toxicity and translating these findings into safer therapeutic strategies. This interest continued during his work as a clinical pharmacologist in a hospital setting, where he contributed to reducing medication errors and strengthening patient safety practices.
During his doctoral training, Dr. Adil investigated endothelial cell biology and its pharmacological modulation, while his postdoctoral research focused on monocyte biology and immune signaling. Recognizing the critical role of endothelial-monocyte interactions in vascular and inflammatory diseases, his independent research program integrates these complementary fields to uncover molecular mechanisms of disease and identify novel therapeutic targets with direct clinical relevance.
One major focus of Dr. Adil's laboratory is the investigation of drug-induced vascular toxicity. His research examines the molecular mechanisms by which doxorubicin induces endothelial dysfunction, with particular emphasis on immune-mediated and intracellular signaling pathways. Although doxorubicin is an effective chemotherapeutic agent, its use is frequently associated with vascular injury and subsequent cardiovascular complications, yet many of the underlying molecular mechanisms remain poorly understood. Using human blood specimens obtained through a Material Transfer Agreement with the University of Tennessee, his laboratory investigates how drug exposure alters endothelial function and contributes to chemotherapy-associated cardiovascular toxicity. This work aims to identify therapeutic strategies that minimize adverse drug effects while highlighting the value of interdisciplinary collaboration in translational research.
A second major area of interest is drug–drug interactions, particularly those involving cytochrome P450 (CYP450) enzymes that regulate drug metabolism. As the use of novel therapeutics continues to expand, understanding their effects on metabolic pathways is essential for improving medication safety. Dr. Adil's laboratory is currently investigating the impact of semaglutide, a widely prescribed GLP-1 receptor agonist for diabetes and obesity, on CYP450 enzyme regulation. Computational analyses have identified several CYP enzymes that are significantly altered following semaglutide treatment in preclinical models, and these findings are currently being validated in human HepaRG liver cells. By integrating bioinformatics with experimental pharmacology, this research seeks to improve the prediction of clinically relevant drug–drug interactions and enhance the safe use of emerging therapies.
Dr. Adil also fosters an environment that encourages students to develop independent research ideas while utilizing the laboratory's available resources. This collaborative approach promotes scientific creativity, critical thinking, and research ownership. One emerging research direction generated through student collaboration investigates the effects of semaglutide on endothelial–monocyte interactions in atherosclerosis, providing new opportunities to understand the anti-inflammatory and vasculo-protective actions of GLP-1 receptor agonists.